Aridis Pharmaceuticals, Inc.
ARDS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $4 | $8 | $10 | $22 |
| - Cash | $0 | $0 | $1 | $5 |
| + Debt | $5 | $6 | $4 | $6 |
| Enterprise Value | $9 | $14 | $12 | $23 |
| Revenue | $0 | $20 | $0 | $0 |
| % Growth | -97.9% | – | – | – |
| Gross Profit | $0 | $20 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | -$1 | $14 | -$6 | -$7 |
| % Margin | -194.2% | 69.9% | – | – |
| Net Income | -$0 | $12 | -$7 | -$6 |
| % Margin | -19.9% | 61.8% | – | – |
| EPS Diluted | -0.002 | 0.33 | -0.22 | -0.35 |
| % Growth | -100.7% | 250% | 37.1% | – |
| Operating Cash Flow | -$1 | -$4 | -$4 | -$9 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$1 | -$4 | -$4 | -$9 |